December 12, 2016 – St. Charles, MO – D2 Consulting, a leading life sciences consulting firm offering both strategic and tactical commercialization services to pharmaceutical, biotechnology and medical device manufacturers, today announced that the Company will participate in the 18th Southeast BIO Investor and Partnering Forum (SEBIO).
SEBIO is the leading life sciences investment conference in the Southeast, and brings together more than 300 biotechnology and medical technology investors, executives and entrepreneurs to discuss partnerships and explore new business opportunities.
Dean Erhardt, president of D2 Consulting, is scheduled to present on Wednesday, December 14th, 2016 at 8:30 a.m. ET at the Hyatt Regency in Jacksonville, Florida. Mr. Erhardt’s presentation will address commercialization hurdles faced by biopharmaceutical manufacturers in driving efficient distribution and attainment of adequate product reimbursement.
About D2 Consulting
Established in 2008, D2 Consulting (D2) is recognized as the industry’s leading provider of commercialization services to the life sciences industry. D2 assists emerging and established pharmaceutical, biopharmaceutical and medical device manufacturers to develop and execute strategic business initiatives, ensuring successful launch, distribution and reimbursement to support an ongoing leadership position in the marketplace.
D2’s reach includes the U.S., Canada, Puerto Rico and more than 20 European markets. With more than 300 successful product launches, the Company offers strategic and tactical support services from a core team of advisors with more than 500 years of combined industry experience in more than 50 therapeutic areas. For more information on D2, please visit www.D2rx.com.
Corporate & Media Relations
D2 Consulting, LLC